logo
A Data-Driven Fix For Orthopedic Practices Losing To Claim Denials

A Data-Driven Fix For Orthopedic Practices Losing To Claim Denials

Forbes7 days ago
Sally Ragab, Founder & CEO @ Neunetix.
Ask any orthopedic group what keeps their CFO up at night, and one answer dominates: denied claims. National surveys show that orthopedics now sees 9% to 11% of all claims rejected. In dollar terms, a 12-surgeon group billing $85 million a year could watch $8 to $10 million slip away before a single appeal is filed.
In a recent article, I explored why the problem is worsening across healthcare. Building on this, a multisite analysis conducted by my company suggests that most leakage is preventable—and faster to plug than many administrators think.
What We Studied
Between April 2024 and March 2025, my company partnered with 12 independent orthopedic practices (across California, Texas, Florida and New York), which collectively submitted 1.26 million claims. We captured every rejection code, payer response time and downstream appeal outcome. Three findings stood out:
1. The overall claim denial rate dropped from 10.4% in the 12 months before the intervention to 6.7% during the six-month intervention period.
2. Preventable denials—such as those caused by missing claim modifiers or lapses in prior authorizations—fell from 64% to 28%.
3. Additionally, the average number of days that claims remained unpaid in accounts receivable decreased from 46 days to 38 days.
To achieve this, all practices followed the same three-step process, which I will outline below. There was no need to hire additional full-time staff or change their electronic health record systems.
Why Orthopedics Gets Hit Harder
1. High-Ticket Procedures: Hip- and knee-replacement bundles average between $30,000 and $32,000. One denial can wipe out the revenue from hundreds of physical therapy sessions—more than a year of visits for the average patient.
2. Modifier Complexity: Orthopedic procedures often involve complex coding and modifier usage, and many of the most frequently flagged CPT codes for CO-4 and PR-22 edits stem from this specialty—especially when modifiers are missing or missequenced.
3. Authorization Churn: Payers continue to ratchet up pre‑service checks. CMS now requires prior authorization for all hospital outpatient cervical spinal‑fusion procedures with disc removal, and insurance policies, like UnitedHealthcare's 2024 commercial policy, list every major arthroscopy CPT code as "prior authorization required." As a result, authorization‑related denials for outpatient claims jumped 16% in the past three years (registration required).
The Three-Step Denial-Prevention Playbook
Run a scrape and review electronic claims and payment files (known as ANSI 835/837 files) to identify which billing modifiers are most commonly linked to denials. In our cohort, simple left/right side coding errors (using -RT for right or -LT for left) accounted for 21% of preventable rejections. A one-hour meeting with the coding team to flag and prevent these errors led to a 2.3% point drop in the denial rate within just one month.
Add a simple yes/no binary check to the scheduling system so that surgeries can't be booked unless a valid prior authorization ID is included. Clinics that enforced this safeguard reduced their authorization-related denials from 3.7% to 0.9% in just 90 days.
A simple predictive model, trained on about 150,000 past claims, was used to flag new claims that were at high risk of denial. Only claims with a risk score of 0.70 or higher were sent to coders for review—everything else moved through automatically. This reduced the average coder workload by 41%, allowing staff to focus more on higher-value appeals.
Financial Impact
Across the 12 practices, net collections rose $6.4 million in the first six months—roughly $0.75 million per practice—while denial-related write-offs fell 52%. The average site reached cash-flow breakeven on the project in 51 days. Those numbers align with industry surveys, indicating that 65% of orthopedic denials are preventable and that 30% are never reworked at all.
Quick Wins Orthopedic Leaders Can Implement Today
As a summary, a focused audit of common billing modifier errors—followed by a short retraining session for coding staff—can lead to a 1.5 to 3 percentage-point drop in overall denials. This typically requires no more than two weeks.
Next, adding a mandatory prior authorization field to the surgical scheduling system ensures that procedures can't be booked without a valid authorization ID. Clinics that adopted this safeguard saw authorization-related denials fall by 1 to 2.5 percentage points, with rollout taking about 30 days, including staff training.
Finally, integrating a simple AI-based risk scoring tool into the claims submission process can further reduce denials by 2 to 4 percentage points. The tool should flag only the highest-risk claims for manual review, cutting coder workload by about 40% and letting teams focus on appeals and other high-value tasks. In my experience, most practices can launch this model within 60 days.
Collectively, these steps can push denial rates below the 7.66% improper payment benchmark CMS reports for 2024.
Why Act Now
• Payer scrutiny is rising. The "State of Claims 2024" report notes a steady climb in authorization-related denials across all specialties, with orthopedics singled out for high-cost implant cases.
• Providers feel the pinch. In Experian's 2024 survey, 73% said denials are rising and 67% said payments are taking longer to arrive.
• CMS audits are looming. Improper payment probes increasingly target spinal and total-joint bundles; denial records factor into audit risk scores.
The Bottom Line
Denied claims shouldn't simply be a cost of doing business—they're a solvable data problem. Our field data proves that taking steps like a disciplined five-day audit, a hard scheduling gate and a modest machine-learning layer can slash orthopedic denial rates by one-third and return millions to the bottom line within a quarter.
Your implants are cutting-edge—your denial-defense strategy should be too.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Yahoo

time19 minutes ago

  • Yahoo

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

Yahoo

time19 minutes ago

  • Yahoo

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call

Yahoo

time19 minutes ago

  • Yahoo

VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) ('Vaalco' or the 'Company') today announced the timing of its second quarter 2025 earnings release and conference call. The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.) Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at An audio replay will be available on the Company's website following the call. About Vaalco Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada. For Further Information Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422 Website: Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422 Al Petrie / Chris Delange Buchanan (UK Financial PR) +44 (0) 207 466 5000 Ben Romney / Barry Archer Vaalco@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store